LA JOLLA, Calif., April 16, 2019 /PRNewswire-PRWeb/ -- Boston-based InfoBionic, developer of the MoMeŽ Kardia remote cardiac monitor and software, won this year's Technology Leadership Award from Frost & Sullivan. The award is presented to the technology firm that best embodies commitment to innovation and creativity, serves as an incubator and developer of new technology, and demonstrates a track record of commercial success.[1]
InfoBionic's MoMeŽ Kardia, is the only full-disclosure remote monitor currently on the market that allows doctors immediate and 24/7 access to cardiac data on demand. It captures a clinical-grade electrocardiogram (ECG) and provides true continuous cardiac monitoring in near real time, which the doctor can access on their tablet, smartphone, or on any Internet-connected computer in the world.
"We're grateful and honored to have received this year's Technology Leadership Award," said Stuart Long, CEO of InfoBionic. "We're very excited to be helping transform the cardiac monitoring industry, and look forward to helping providers implement this potentially life-saving technology into their own work flows."
Each year, Frost & Sullivan presents Best Practices Awards to companies that are expected to encourage significant growth in their industries, have identified emerging trends before they became the marketplace standard, and have created advanced technologies that will catalyze and transform industries in the near future. This year's awards were presented on March 27, 2019 at a gala event at the Hyatt Regency in La Jolla, California.
Arrhythmia
MoMeŽ Kardia is designed to help doctors detect and diagnose cardiac arrhythmia, which is characterized by irregular electrical activity in the heart that causes it to beat too rapidly, too slowly, or erratically.
Benefits of the MoMeŽ Kardia
InfoBionic's innovations in data analytics, in artificial intelligence, and in secure, HIPAA-compliant telecommunications enabled it to bring a device to market that is poised to transform the entire cardiac monitoring industry. MoMeŽ Kardia's documented benefits include:
Among the most important innovations: The MoMeŽ Kardia provides a continuous data feed for up to 30 days, and it does not rely on a patient clicking a button to indicate they are feeling symptoms. This is a significant improvement over legacy technology because with this, patients either have to manually activate monitors after they begin experiencing symptoms or they just do not activate the monitor when there is an arrhythmia they do not feel. This causes doctors to miss important onset data and makes it much more difficult to assess and treat arrhythmia properly. The MoMeŽ Kardia's continuous feed, coupled with on-demand 24/7 access to every heartbeat, makes it much easier for physicians to capture critical data, analyze it, diagnose it, and initiate treatment.
Clinical Impact
Dr. Michael Mazzini, MD, a cardiologist who uses the MoMeŽ Kardia in his own practice, describes his experiences:
"Last week I put Mobile Cardiac Telemetry (MCT) on a patient on a Friday. It picked up 10 to 14 second asystolic events the following morning, and I was able to get a pacemaker in him that morning," relates Dr. Mazzini. "No hospital telemetry stay, no emergency department visit, no unnecessary workups, no delay in diagnosis Less than 24 hours from MCT hookup to definitive treatment. That's tremendous value to patients, clinicians, hospitals, and payers," he said.
"Patients and physicians are now equipped with greater control over heart monitoring for improved outcomes," said Frost & Sullivan in a release announcing the award decision.[2]
About InfoBionic InfoBionic is a digital health company transforming the efficiency and economics of ambulatory remote patient monitoring processes by optimizing clinical and real-world utility for the users that need it mostphysicians and their patients. The Massachusetts-based team of seasoned entrepreneurs have had successful careers in healthcare, IT, medical devices and mobile technology, and bring specific expertise in remote monitoring and cardiology. They have seen first-hand the complexities of traditional cardiac arrhythmia detection and monitoring processes and designed the transformative MoMeŽ Kardia platform to remove the roadblocks hindering faster, more effective diagnosis and decision-making. Frost & Sullivan bestowed the 2019 North American Remote Cardiac Monitoring Technology Leadership Award upon InfoBionic. For more information visit http://www.infobionic.com
About MoMeŽ Kardia The company's flagship product, MoMeŽ Kardia, is the first non-invasive remote cardiac monitor to offer truly full disclosure, heartbeat-to-heartbeat data over the cloud, allowing doctors 24/7 real-time access to hospital telemetry-level data. With the MoMeŽ Kardia, doctors will be able to eliminate third-party monitoring data services and take full ownership of their cardiac monitoring service line. MoMeŽ Kardia is not intended for use as an emergency medical response system. Call 911 if you feel you are having a medical emergency.
Sources:
1. Frost & Sullivan, Frost & Sullivan Recognizes Industry Leaders at Excellence in Best Practices Awards Ceremony. March 28, 2019, Web.
2. Frost & Sullivan, Technology Leadership Award The Remote Cardiac Monitoring Industry, North America. 2018.
SOURCE InfoBionic
Advertisement
InfoBionic's MoMeŽ Kardia, is the only full-disclosure remote monitor currently on the market that allows doctors immediate and 24/7 access to cardiac data on demand. It captures a clinical-grade electrocardiogram (ECG) and provides true continuous cardiac monitoring in near real time, which the doctor can access on their tablet, smartphone, or on any Internet-connected computer in the world.
Advertisement
"We're grateful and honored to have received this year's Technology Leadership Award," said Stuart Long, CEO of InfoBionic. "We're very excited to be helping transform the cardiac monitoring industry, and look forward to helping providers implement this potentially life-saving technology into their own work flows."
Each year, Frost & Sullivan presents Best Practices Awards to companies that are expected to encourage significant growth in their industries, have identified emerging trends before they became the marketplace standard, and have created advanced technologies that will catalyze and transform industries in the near future. This year's awards were presented on March 27, 2019 at a gala event at the Hyatt Regency in La Jolla, California.
Arrhythmia
MoMeŽ Kardia is designed to help doctors detect and diagnose cardiac arrhythmia, which is characterized by irregular electrical activity in the heart that causes it to beat too rapidly, too slowly, or erratically.
Benefits of the MoMeŽ Kardia
InfoBionic's innovations in data analytics, in artificial intelligence, and in secure, HIPAA-compliant telecommunications enabled it to bring a device to market that is poised to transform the entire cardiac monitoring industry. MoMeŽ Kardia's documented benefits include:
- The physician has access to all data at any given point of time. Full data disclosure sets MoMeŽ Kardia apart from market competition because all other devices only share event triggers with the patient. Full data has to be requested, and even then it may take time to receive. By giving physicians complete access to patients' health data, InfoBionic empowers them with true 24x7 monitoring and faster intervention.
- It has vast improvements in data retention. In the past, 95% to 99% of cardiac data is lost in transmission. Independent diagnostic and testing facilities servicing monitors may send a 20 or 30 second tape of a detected arrhythmia. However, doctors too often missed critical onset and offset data in the minutes prior to the cardiac eventthis data is vital to diagnosis.
- The time-to-diagnosis cycle is improved, and in some cases by days. Doctors do not have to get bogged down in faxes, emails, and phone calls from third-party monitoring services vendors. They can easily access the digital ECG tape itself, and scroll forward and backward to any part of the day to verify arrhythmia data and view onset and offset information.
- The physician can conveniently gain access to monitoring data any time of the day and can remotely switch between testing modes (MCT, Holter, or Event) as needed. The system's remote transition capability eliminates the need for patients to visit a hospital and the physician can decide the treatment based on the arrhythmia detection relevance. This effectively replicates the practice of in-hospital monitoring, making patients unencumbered while they are studied in their natural state of activity.
- Doctors using the MoMeŽ Kardia can bill globally for both clinical and technical services.
Among the most important innovations: The MoMeŽ Kardia provides a continuous data feed for up to 30 days, and it does not rely on a patient clicking a button to indicate they are feeling symptoms. This is a significant improvement over legacy technology because with this, patients either have to manually activate monitors after they begin experiencing symptoms or they just do not activate the monitor when there is an arrhythmia they do not feel. This causes doctors to miss important onset data and makes it much more difficult to assess and treat arrhythmia properly. The MoMeŽ Kardia's continuous feed, coupled with on-demand 24/7 access to every heartbeat, makes it much easier for physicians to capture critical data, analyze it, diagnose it, and initiate treatment.
Clinical Impact
Dr. Michael Mazzini, MD, a cardiologist who uses the MoMeŽ Kardia in his own practice, describes his experiences:
"Last week I put Mobile Cardiac Telemetry (MCT) on a patient on a Friday. It picked up 10 to 14 second asystolic events the following morning, and I was able to get a pacemaker in him that morning," relates Dr. Mazzini. "No hospital telemetry stay, no emergency department visit, no unnecessary workups, no delay in diagnosis Less than 24 hours from MCT hookup to definitive treatment. That's tremendous value to patients, clinicians, hospitals, and payers," he said.
"Patients and physicians are now equipped with greater control over heart monitoring for improved outcomes," said Frost & Sullivan in a release announcing the award decision.[2]
About InfoBionic InfoBionic is a digital health company transforming the efficiency and economics of ambulatory remote patient monitoring processes by optimizing clinical and real-world utility for the users that need it mostphysicians and their patients. The Massachusetts-based team of seasoned entrepreneurs have had successful careers in healthcare, IT, medical devices and mobile technology, and bring specific expertise in remote monitoring and cardiology. They have seen first-hand the complexities of traditional cardiac arrhythmia detection and monitoring processes and designed the transformative MoMeŽ Kardia platform to remove the roadblocks hindering faster, more effective diagnosis and decision-making. Frost & Sullivan bestowed the 2019 North American Remote Cardiac Monitoring Technology Leadership Award upon InfoBionic. For more information visit http://www.infobionic.com
About MoMeŽ Kardia The company's flagship product, MoMeŽ Kardia, is the first non-invasive remote cardiac monitor to offer truly full disclosure, heartbeat-to-heartbeat data over the cloud, allowing doctors 24/7 real-time access to hospital telemetry-level data. With the MoMeŽ Kardia, doctors will be able to eliminate third-party monitoring data services and take full ownership of their cardiac monitoring service line. MoMeŽ Kardia is not intended for use as an emergency medical response system. Call 911 if you feel you are having a medical emergency.
Sources:
1. Frost & Sullivan, Frost & Sullivan Recognizes Industry Leaders at Excellence in Best Practices Awards Ceremony. March 28, 2019, Web.
2. Frost & Sullivan, Technology Leadership Award The Remote Cardiac Monitoring Industry, North America. 2018.
SOURCE InfoBionic
